FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385514238> ?p ?o ?g. }

• W4385514238 endingPage "e2327145" @default.
• W4385514238 startingPage "e2327145" @default.
• W4385514238 abstract "Importance Anti–programmable cell death-1 (anti–PD-1) improves relapse-free survival when used as adjuvant therapy for high-risk resected melanoma. However, it can lead to immune-related adverse events (irAEs), which become chronic in approximately 40% of patients with high-risk melanoma treated with adjuvant anti–PD-1. Objective To determine the incidence, characteristics, and long-term outcomes of chronic irAEs from adjuvant anti–PD-1 therapy. Design, Setting, and Participants This retrospective multicenter cohort study analyzed patients treated with adjuvant anti–PD-1 therapy for advanced and metastatic melanoma between 2015 and 2022 from 6 institutions in the US and Australia with at least 18 months of evaluable follow-up after treatment cessation (range, 18.2 to 70.4 months). Main Outcomes and Measures Incidence, spectrum, and ultimate resolution vs persistence of chronic irAEs (defined as those persisting at least 3 months after therapy cessation). Descriptive statistics were used to analyze categorical and continuous variables. Kaplan-Meier curves assessed survival, and Wilson score intervals were used to calculate CIs for proportions. Results Among 318 patients, 190 (59.7%) were male (median [IQR] age, 61 [52.3-72.0] years), 270 (84.9%) had a cutaneous primary, and 237 (74.5%) were stage IIIB or IIIC at presentation. Additionally, 226 patients (63.7%) developed acute irAEs arising during treatment, including 44 (13.8%) with grade 3 to 5 irAEs. Chronic irAEs, persisting at least 3 months after therapy cessation, developed in 147 patients (46.2%; 95% CI, 0.41-0.52), of which 74 (50.3%) were grade 2 or more, 6 (4.1%) were grade 3 to 5, and 100 (68.0%) were symptomatic. With long-term follow-up (median [IQR], 1057 [915-1321] days), 54 patients (36.7%) experienced resolution of chronic irAEs (median [IQR] time to resolution of 19.7 [14.4-31.5] months from anti–PD-1 start and 11.2 [8.1-20.7] months from anti–PD-1 cessation). Among patients with persistent irAEs present at last follow-up (93 [29.2%] of original cohort; 95% CI, 0.25-0.34); 55 (59.1%) were grade 2 or more; 41 (44.1%) were symptomatic; 24 (25.8%) were using therapeutic systemic steroids (16 [67%] of whom were on replacement steroids for hypophysitis (8 [50.0%]) and adrenal insufficiency (8 [50.0%]), and 42 (45.2%) were using other management. Among the 54 patients, the most common persistent chronic irAEs were hypothyroid (38 [70.4%]), arthritis (18 [33.3%]), dermatitis (9 [16.7%]), and adrenal insufficiency (8 [14.8%]). Furthermore, 54 [17.0%] patients experienced persistent endocrinopathies, 48 (15.1%) experienced nonendocrinopathies, and 9 (2.8%) experienced both. Of 37 patients with chronic irAEs who received additional immunotherapy, 25 (67.6%) experienced no effect on chronic irAEs whereas 12 (32.4%) experienced a flare in their chronic toxicity. Twenty patients (54.1%) experienced a distinct irAE. Conclusions and Relevance In this cohort study of 318 patients who received adjuvant anti–PD-1, chronic irAEs were common, affected diverse organ systems, and often persisted with long-term follow-up requiring steroids and additional management. These findings highlight the likelihood of persistent toxic effects when considering adjuvant therapies and need for long-term monitoring and management." @default.
• W4385514238 created "2023-08-04" @default.
• W4385514238 creator A5002175238 @default.
• W4385514238 creator A5008479799 @default.
• W4385514238 creator A5011641659 @default.
• W4385514238 creator A5019074191 @default.
• W4385514238 creator A5022520811 @default.
• W4385514238 creator A5025067315 @default.
• W4385514238 creator A5038759671 @default.
• W4385514238 creator A5042621368 @default.
• W4385514238 creator A5045256816 @default.
• W4385514238 creator A5053602981 @default.
• W4385514238 creator A5056334685 @default.
• W4385514238 creator A5070576000 @default.
• W4385514238 creator A5080635562 @default.
• W4385514238 creator A5083061830 @default.
• W4385514238 creator A5089902724 @default.
• W4385514238 creator A5090545021 @default.
• W4385514238 date "2023-08-03" @default.
• W4385514238 modified "2023-10-09" @default.
• W4385514238 title "Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma" @default.
• W4385514238 cites W2797309423 @default.
• W4385514238 cites W2895125473 @default.
• W4385514238 cites W3087697977 @default.
• W4385514238 cites W3137634582 @default.
• W4385514238 cites W3197265554 @default.
• W4385514238 cites W3217534140 @default.
• W4385514238 cites W4210370153 @default.
• W4385514238 cites W4220803681 @default.
• W4385514238 cites W4307430006 @default.
• W4385514238 doi "https://doi.org/10.1001/jamanetworkopen.2023.27145" @default.
• W4385514238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37535354" @default.
• W4385514238 hasPublicationYear "2023" @default.
• W4385514238 type Work @default.
• W4385514238 citedByCount "1" @default.
• W4385514238 countsByYear W43855142382023 @default.
• W4385514238 crossrefType "journal-article" @default.
• W4385514238 hasAuthorship W4385514238A5002175238 @default.
• W4385514238 hasAuthorship W4385514238A5008479799 @default.
• W4385514238 hasAuthorship W4385514238A5011641659 @default.
• W4385514238 hasAuthorship W4385514238A5019074191 @default.
• W4385514238 hasAuthorship W4385514238A5022520811 @default.
• W4385514238 hasAuthorship W4385514238A5025067315 @default.
• W4385514238 hasAuthorship W4385514238A5038759671 @default.
• W4385514238 hasAuthorship W4385514238A5042621368 @default.
• W4385514238 hasAuthorship W4385514238A5045256816 @default.
• W4385514238 hasAuthorship W4385514238A5053602981 @default.
• W4385514238 hasAuthorship W4385514238A5056334685 @default.
• W4385514238 hasAuthorship W4385514238A5070576000 @default.
• W4385514238 hasAuthorship W4385514238A5080635562 @default.
• W4385514238 hasAuthorship W4385514238A5083061830 @default.
• W4385514238 hasAuthorship W4385514238A5089902724 @default.
• W4385514238 hasAuthorship W4385514238A5090545021 @default.
• W4385514238 hasBestOaLocation W43855142381 @default.
• W4385514238 hasConcept C120665830 @default.
• W4385514238 hasConcept C121332964 @default.
• W4385514238 hasConcept C121608353 @default.
• W4385514238 hasConcept C126322002 @default.
• W4385514238 hasConcept C141071460 @default.
• W4385514238 hasConcept C143998085 @default.
• W4385514238 hasConcept C167135981 @default.
• W4385514238 hasConcept C197934379 @default.
• W4385514238 hasConcept C2777658100 @default.
• W4385514238 hasConcept C2777863537 @default.
• W4385514238 hasConcept C2777982462 @default.
• W4385514238 hasConcept C502942594 @default.
• W4385514238 hasConcept C61511704 @default.
• W4385514238 hasConcept C71924100 @default.
• W4385514238 hasConcept C72563966 @default.
• W4385514238 hasConceptScore W4385514238C120665830 @default.
• W4385514238 hasConceptScore W4385514238C121332964 @default.
• W4385514238 hasConceptScore W4385514238C121608353 @default.
• W4385514238 hasConceptScore W4385514238C126322002 @default.
• W4385514238 hasConceptScore W4385514238C141071460 @default.
• W4385514238 hasConceptScore W4385514238C143998085 @default.
• W4385514238 hasConceptScore W4385514238C167135981 @default.
• W4385514238 hasConceptScore W4385514238C197934379 @default.
• W4385514238 hasConceptScore W4385514238C2777658100 @default.
• W4385514238 hasConceptScore W4385514238C2777863537 @default.
• W4385514238 hasConceptScore W4385514238C2777982462 @default.
• W4385514238 hasConceptScore W4385514238C502942594 @default.
• W4385514238 hasConceptScore W4385514238C61511704 @default.
• W4385514238 hasConceptScore W4385514238C71924100 @default.
• W4385514238 hasConceptScore W4385514238C72563966 @default.
• W4385514238 hasIssue "8" @default.
• W4385514238 hasLocation W43855142381 @default.
• W4385514238 hasLocation W43855142382 @default.
• W4385514238 hasOpenAccess W4385514238 @default.
• W4385514238 hasPrimaryLocation W43855142381 @default.
• W4385514238 hasRelatedWork W1996336352 @default.
• W4385514238 hasRelatedWork W2013259535 @default.
• W4385514238 hasRelatedWork W2056489416 @default.
• W4385514238 hasRelatedWork W2134501231 @default.
• W4385514238 hasRelatedWork W2159893604 @default.
• W4385514238 hasRelatedWork W2168593612 @default.
• W4385514238 hasRelatedWork W2189560216 @default.
• W4385514238 hasRelatedWork W2395564121 @default.
• W4385514238 hasRelatedWork W2397756962 @default.

• next